Company intelligence / Profile preview

Vinci Pharmaceuticals

USA

Ownership: Private
Development stage: Other

Overview

Vinci Pharmaceuticals is developing EPIPLANT™, a proprietary needle free drug delivery platform targeting major retinal diseases. No public clinical trial results are available as of August 2025; the platform claims a safe and effective delivery approach to the retina without injections.

Therapeutic areas: Ophthalmology
Modalities: DevicePlatform technology (needle free drug delivery)
Industry: Therapeutic Medical Devices

Beyond the preview

Go deeper on Vinci Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vinci Pharmaceuticals.

Explore the full profile